🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Idefirix 11 mg powder for concentrate for solution for infusion

    Hansa Biopharma AB

    End stage chronic kidney disease (CKD) patients who are highly sensitised and on the kidney transplant list awaiting a kidney transplant

    phase 3 small molecule active

    1 trial

  2. Identical to NBI-1065845 tablets without active drug, NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  3. Identical to kai-9531 solution for injection without active drug, KAI-9531, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  4. Identical to the Test product, XGEVA 120 mg solution for injection

    Shanghai Reinovax Biologics Co.,LTD

    Prevention of breast cancer in women with a BRCA1 germline mutation

    phase 3 small molecule active

    1 trial

  5. Ifinatamab deruxtecan, IRINOTECAN HYDROCHLORIDE, DOCETAXEL, PACLITAXEL

    Daiichi Sankyo

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule active

    1 trial

  6. IkT-001Pro, Placebo to match 100 mg IKT-001 tablets

    Inhibikase Therapeutics

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  7. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Bipolar I Disorder

    phase 3 small molecule completed

    2 trials

  8. Ilumetri 100 mg solution for injection in pre-filled syringe, Tildrakizumab placebo solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  9. Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe

    Lacuna Pharma Pty Ltd

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  10. Imatinib

    United Therapeutics Europe Ltd

    Myeloid Leukemia, Chronic, Chronic Phase

    phase 3 small molecule completed

    1 trial

  11. Imatinib Mesylate Tablets, 400 mg

    Amneal Pharma Europe Ltd

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  12. Imetelstat

    Geron Netherlands B.V.

    Myelofibrosis

    phase 3 small molecule active

    1 trial

  13. Imiquimod 5% cream

    Grace Therapeutics

    Superficial Basal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  14. Imiquimod Cream, 3.75%

    Teva Pharma GmbH

    Actinic Keratosis

    phase 3 small molecule completed

    1 trial

  15. Immune Globulin 10% Intravenous Solution

    Vera Therapeutics

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  16. Immune Globulin Infusion (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  17. Immune Globulin Intravenous (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  18. Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Takeda

    Alzheimer´s Disease

    phase 3 small molecule terminated

    1 trial

  19. Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Takeda

    Alzheimer´s Disease

    phase 3 mab completed

    1 trial

  20. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  21. Immune Globulin Intravenous (Human), 10% Solution

    Takeda

    Alzheimer´s Disease

    phase 3 mab terminated

    1 trial

  22. Immune Globulin Intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  23. Immune Globulin Intravenous (human), 10%

    Takeda

    Multifocal Motor Neuropathy

    phase 3 mab completed

    1 trial

  24. Immune Globulin Subcutaneous (Human), 20%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources